Proteomics

Dataset Information

0

Phosphoproteomics Data of pancreatic cancers cells treated with anlotinib


ABSTRACT: Aberrant regulation of angiogenesis involves in the growth and metastasis of tumors, but angiogenesis inhibitors fail to improve overall survival of pancreatic cancer patients in previous phase III clinical trials. A comprehensive knowledge of the mechanism of angiogenesis inhibitors against pancreatic cancer is helpful for clinical purpose and for the selection of patients who might benefit from the inhibitors. In this work, multi-omics analyses (transcriptomics, proteomics and phosphoproteomics profiling) were carried to delineate the mechanism of anlotinib, a novel angiogenesis inhibitor, against pancreatic cancer cells.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Zewen Song  

LAB HEAD: Zewen Song

PROVIDER: PXD023345 | Pride | 2021-09-09

REPOSITORIES: Pride

altmetric image

Publications

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature.

Zhang Xi X   Liu Yang Y   Zhang Zhen Z   Tan Juan J   Zhang Junjun J   Ou Hao H   Li Jie J   Song Zewen Z  

Frontiers in cell and developmental biology 20210304


Aberrant regulation of angiogenesis involves in the growth and metastasis of tumors, but angiogenesis inhibitors fail to improve overall survival of pancreatic cancer patients in previous phase III clinical trials. A comprehensive knowledge of the mechanism of angiogenesis inhibitors against pancreatic cancer is helpful for clinical purpose and for the selection of patients who might benefit from the inhibitors. In this work, multi-omics analyses (transcriptomics, proteomics, and phosphoproteomi  ...[more]

Similar Datasets

2021-09-09 | PXD023344 | Pride
2022-09-06 | PXD025224 | Pride
2022-02-17 | PXD025968 | Pride
2023-10-24 | PXD039060 | Pride
2007-03-21 | E-TABM-155 | biostudies-arrayexpress
2023-09-02 | PXD043836 | Pride
2021-09-09 | PXD020585 | Pride
2024-01-26 | PXD033011 | Pride
2024-01-26 | PXD032935 | Pride
2019-11-14 | PXD010724 | Pride